Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Glycostem Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
LUMICKS Enters Collaboration with Glycostem to Enhance NK cell-Mediated Immunotherapy
Details : Glycostem will assess their NK cells using LUMICKS’ z-Movi to gain new insights into the cell avidity and functional properties of their cells. Avidity is a new parameter that is crucial to understand immune cells better and choose the most potent ones...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 30, 2020
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Glycostem Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration